SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Pharmaids Pharmaceuticals Ltd (524572) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

BSE: 524572 NSE: | Pharmaceuticals & Drugs | Small Cap

Pharmaids Pharma Share Price

30.80 -0.19 (-0.61%)
As on 13-Apr'26 16:59

Pharmaids Pharmaceuticals Ltd (524572)

BSE: 524572 NSE:
Key Metrics
Market Cap
₹109 Cr.
P/E Ratio
0.00
Price to Book (P/B)
1.99
Price to Sales (P/S)
13.50
EV/EBITDA
-10.39
Return on Capital Employed (ROCE)
-6.89%
Current Price
₹30.8
Return on Equity (ROE)
-10.80%
Return on Assets (ROA)
-7.48%
Operating Profit Margin
-310%
Net Profit Margin
-310.96%
Gross Profit Margin
-358.3%
Book Value per Share
₹15.5
Sales Growth (YoY)
7700%
Sales Growth (3 Years)
-15.94%
Operating Profit Growth (1 Year)
NA%
Operating Profit Growth (3 Years)
NAN%
Net Profit Growth (1 Year)
NA%
52-Week Low / High
₹27 / 73
Net Profit Growth (3 Years)
NAN%
Dividend Yield
0.00%
Promoter Holding
32.99%
Pledged shares (%)
of Promoter's holding (%)
0.00%

Check Before You Invest

Q.1
Pharmaids Pharmaceuticals Ltd revenue growth is 7,700% for FY-2025 , which is above its 5 year CAGR of 0% , indicating faster growth.
Q.1
Promoters hold 32.99% of the Pharmaids Pharmaceuticals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1
Pharmaids Pharmaceuticals Ltd revenue CAGR is 0.00% , compared to the industry median CAGR of 5.54% , indicating slower growth and losing its market share.
Q.1
Pharmaids Pharmaceuticals Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.1
Over the last 9 years, the stock has delivered a CAGR of 19% based on the current price.

DeciZen - make an informed investing decision on Pharmaids Pharma

Based on:

Overall Rating
M-Cap below 500cr. High Risk from low Liquidity

1. Quality

2. Valuation

Fair

3. Price Trend

Weak

Pharmaids Pharmaceuticals stock performance

Key Ratios
mw4me loader

Is Pharmaids Pharmaceuticals Ltd an attractive stock to invest in?

1. Is Pharmaids Pharmaceuticals Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Pharmaids Pharmaceuticals Ltd is a below average quality company.

2. Is Pharmaids Pharmaceuticals Ltd undervalued or overvalued?

The key valuation ratios of Pharmaids Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Pharmaids Pharmaceuticals Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Pharmaids Pharmaceuticals Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray :

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Pharmaids Pharmaceuticals Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % -21.2%7.6%-29.7%-3%-4.5%1%1.7%-64%-10.9%-6.9%-
Value Creation
Index
-2.5-0.5-3.1-1.2-1.3-0.9-0.9-5.6-1.8-1.5-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 1.71.20.50.608.63.9002.38
Sales YoY Gr.--28.6%-62.5%24.4%-100%NA-53.9%-100%NA7,700%-
Adj EPS -1.2-0.8-1.1-0.200.10.1-3.5-1.4-2.1-3.5
YoY Gr.-NANANANA200%55.6%-2614.3%NANA-
BVPS (₹) 3.94.33.18.28.28.38.410.220.218.115.5
Adj Net
Profit
-0.4-0.3-0.4-0.200.10.2-7.6-5-7.3-12
Cash Flow from Ops. 00.3-0.2-0.1-0.80.4-0.3-4-3.4-7.7-
Debt/CF from Ops. 28.60000000-3.6-5.1-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 3.8%NA-15.9%7700%
Adj EPS NA-333%-345.1%NA
BVPS18.5%17.1%28.9%-10.2%
Share Price 19% 21.2% 16.1% -53%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
-26.2-18.5-31.2-3.80.41.11.7-48.6-10.6-10.8-20.5
Op. Profit
Mgn %
-20.5-28.6-86-18.101.33.50-22912.2-310-195.8
Net Profit
Mgn %
-23.6-21.1-85.9-31.601.13.70-17806.3-311-151.2
Debt to
Equity
0.400000000.20.6-
Working Cap
Days
3854701,0032,9550334831071,1883,1202,145
Cash Conv.
Cycle
2092143593450312014,850655-432

Recent Performance Summary

Sales growth is good in last 4 quarters at 586.68%

Return on Equity is Poor

Sales growth has been subdued in last 3 years -15.94%

Latest Financials

Standalone Consolidated
TTM EPS (₹) -3.5 -3.9
TTM Sales (₹ Cr.) 8.1 25.5
BVPS (₹) 15.5 14
Reserves (₹ Cr.) 19 14
P/BV 1.99 2.20
PE 0.00 0.00
From the Market
52 Week Low / High (₹) 27.10 / 73.45
All Time Low / High (₹) 1.00 / 87.46
Market Cap (₹ Cr.) 109
Equity (₹ Cr.) 35.3
Face Value (₹) 10
Industry PE 41.4

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Pharmaids Pharma - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales2101094002
Operating Expenses + 221108410610
Manufacturing Costs0000000000
Material Costs1100084102
Employee Cost 0000000123
Other Costs 1100000844
Operating Profit -0-0-0-0-000-10-6-7
Operating Profit Margin (%) -20.5%-28.6%-86.0%-18.1%-1.3%3.5%--22,912.2%-310.0%
Other Income + 0000000011
Exceptional Items 0100000000
Interest 0000000002
Depreciation 0000000000
Profit Before Tax -00-0-0-000-10-6-9
Tax -0-000-0-0-0-2-1-1
Profit After Tax -00-0-0000-8-5-7
PAT Margin (%) -23.6%9.1%-85.9%-31.6%-1.1%3.7%--17,805.0%-311.0%
Adjusted EPS (₹)-1.20.3-1.2-0.20.00.10.1-3.5-1.4-2.1
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund + 1118899227164
Share Capital 33310101010213535
Reserves -2-2-2-2-2-2-213629
Debt +000000001339
Long Term Debt000000001339
Short Term Debt0000000000
Minority Interest0000000000
Trade Payables00000122011
Others Liabilities 0000-0-0-0-2-2-1
Total Liabilities 221989112281114

Fixed Assets

Net Fixed Assets +000000001724
Gross Block200011101725
Accumulated Depreciation2000000000
CWIP 0000000224
Investments 000000035353
Inventories00000010010
Trade Receivables1111001200
Cash Equivalents 01000001320
Others Assets 00178782723
Total Assets 221989112281114

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity + 00-0-0-10-0-4-3-8
PBT -00-0-0-000-10-6-9
Adjustment 00-00000032
Changes in Working Capital 0000-00-06-0-1
Tax Paid 00-00000000
Cash Flow From Investing Activity + -00-0-01-00-5-73-19
Capex -00-0-0-0-00-2-16-9
Net Investments 0000000000
Others 0-0-001-00-3-56-10
Cash Flow From Financing Activity + 0-0-0-0-000216625
Net Proceeds from Shares 000000021540
Net Proceeds from Borrowing 0000000000
Interest Paid -0-000-0000-0-2
Dividend Paid 0000000000
Others 0-0-0-000001227
Net Cash Flow -00-0-0-00012-10-2

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)-26.217.99-31.24-3.760.41.11.69-49.34-10.64-10.8
ROCE (%)-21.197.61-29.73-3.02-4.451.041.66-63.95-10.87-6.89
Asset Turnover Ratio0.70.560.270.1101.010.4000.02
PAT to CFO Conversion(x)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Working Capital Days
Receivable Days237283530457012750024
Inventory Days6381000165803,011779
Payable Days13524223417601114386101,049

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Pharmaids Pharmaceuticals Ltd FAQs

The current trading price of Pharmaids Pharma on 13-Apr-2026 16:59 is ₹30.80.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 12-Apr-2026 the market cap of Pharmaids Pharma stood at ₹108.6 Cr

The latest P/E ratio of Pharmaids Pharma as of 12-Apr-2026 is 0.00.

The latest P/B ratio of Pharmaids Pharma as of 12-Apr-2026 is 1.99.

The 52-week high of Pharmaids Pharma is ₹73.45 and the 52-week low is ₹27.10.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Pharmaids Pharma is ₹8.05 ( Cr.) .

About Pharmaids Pharmaceuticals Ltd

Pharmaids Pharmaceuticals Limited Incorporated in the year 1989 at Hyderabad (Telangana, India). The company is suppliers of Quality Grade range of Specialty chemicals, Skin care, Hospital care and Generic products in the areas of Orthopedic, Neuro and Gastro etc. Its technical team uses quality proven chemical compounds and standard processing methods maintaining proper hygienic standards. Its professionals strive to offer best quality and high purity to attain maximum client's satisfaction. The company’s offered product range is highly acknowledged in the market for its precise composition long shelf life, hygienic processing techniques, premium quality and high purity.

Business area of the company

The Company is engaged in the business of Trading and Manufacturing of Generics, Bulk Drugs and Intermediaries, etc.

Products

  • Speciality Chemicals
  • Skin Care Products
  • Hospital Care Products
  • Generics
You have 1 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×